Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising

An antigen, antibody technology, applied in the field of preparing this anti-ADAM12 agent or composition, expanding such cells, chimeric antigen receptor, treatment, stimulating immune response, preventing or diagnosing diseases such as cancer

Pending Publication Date: 2022-02-01
JAVELIN ONCOLOGY INC
View PDF66 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although CAR T cell therapy also shows great promise in the treatment of solid tumors (Louis C.U. et al., Blood., 2011 Dec. 1; 118(23):6050-6056, online pre-published Oct. 7, 2011, doi:10.1182 / blood-2011-05-354449), but additional challenges have been encountered in treating these indications (Yong C.S.M. et al., Immunol Cell Biol. 2017 Apr;95(4):356-363 , doi:10.1038 / icb.2016.128, epublished December 22, 2016): Presence of an immunosuppressive tumor microenvironment; problems with accessing tumors; and lack of tumor-selective targets needed to minimize 'off-tumor' toxicity Towards

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising
  • Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising
  • Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0351] In some embodiments, the method of preparation includes the step of freezing (eg, cryopreserving) the cells before or after isolation, incubation, and / or engineering. In some embodiments, the freezing and subsequent thawing steps remove granulocytes and, to some extent, monocytes from the cell population. In some embodiments, cells are suspended in a freezing solution, eg, followed by a washing step to remove plasma and platelets. In some aspects, any of a variety of known freezing solutions and parameters can be used. One example involves the use of PBS or other suitable cell freezing medium containing 20% ​​DMSO and 8% human serum albumin (HSA). It was then diluted 1:1 with culture medium so that the final concentrations of DMSO and HSA were 10% and 4%, respectively. The cells were then frozen at -80°C at a rate of 1 degree per minute and stored in the gas phase of a liquid nitrogen tank.

[0352] Isolation of Ab or Antigen-Binding Ab Fragments from Cell Culture ...

Embodiment 1

[0517] Example 1: Humanization of Mouse Anti-ADAM12 Antibody

[0518]

[0519] Mouse anti-ADAM12 antibody (clone 6E6) sequence

[0520] Heavy chain (HC) variable domain (VH): SEQ ID NO: 111, encoded by SEQ ID NO: 211

[0521] CDR 1, CDR 2 and CDR 3 of VH: SEQ ID NO: 112, 113 and 114, encoded by SEQ ID NO: 212, 213 and 214

[0522] Light chain (LC) variable domain (VL): SEQ ID NO: 115, encoded by SEQ ID NO: 215

[0523] CDR 1 , CDR 2 and CDR 3 of VL: SEQ ID NO: 116, 117 and 118, encoded by SEQ ID NO: 216, 217 and 218

[0524] Mouse anti-ADAM12 antibody (clone 6C10) sequence

[0525] Heavy chain (HC) variable domain (VH): SEQ ID NO: 121, encoded by SEQ ID NO: 221

[0526] CDR 1, CDR 2 and CDR 3 of VH: SEQ ID NO: 122, 123 and 124, encoded by SEQ ID NO: 222, 223 and 224

[0527] Light chain (LC) variable domain (VL): SEQ ID NO: 125, encoded by SEQ ID NO: 225

[0528] CDR 1 , CDR 2 and CDR 3 of VL: SEQ ID NO: 126, 127 and 128, encoded by SEQ ID NO: 226, 227 and 228

[...

Embodiment 2

[0543] Example 2: ADAM12 Expression on Cancer Cell Lines

[0544]

[0545] MCF7-ADAM12 cells (human breast cancer cell line MCF7 transfected with ADAM12 expression vector) and U87-MG cells (human glioblastoma cell line)

[0546] Mouse anti-human ADAM12 IgG primary antibody (clone 6C10)

[0547] Unpurified ascites samples collected from mice containing cells producing mouse anti-human ADAM12 antibodies (clone 7B8 or 8F8)

[0548] FITC-labeled anti-mouse IgG secondary antibody

[0549]

[0550] Cells were first stained with mouse anti-human ADAM12 IgG primary antibody (clone 6C10) or unpurified ascites samples collected from mice containing anti-human ADAM12 antibody-producing cells (clone 7B8 or 8F8). Cells were then stained with FITC-labeled anti-mouse IgG and analyzed by flow cytometry.

[0551]

[0552] The results of flow cytometry were as Figure 5 shown. All cells were positive for ADAM12 expression after staining.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Anti-ADAM12 agents are provided such as anti-ADAM12 antibodies (Abs), antigen- binding Ab fragments, multi-specific Abs and antigen-binding Ab fragments, antibody- drug conjugates (ADCs), and chimeric antigen receptors (CARs). Also, nucleic acid sequences and vectors are provided encoding, cells and pharmaceutical compositions comprising such anti-ADAM12 agents and methods for expanding such cells. Methods of treating, preventing, or diagnosing a disease such as cancer and methods of stimulating an immune response using such materials are also provided.

Description

[0001] related application [0002] This application claims priority to U.S. Provisional Patent Application 62 / 821,257, filed March 20, 2019, entitled "ANTI-ADAM12 ANTIBODIES ANDCHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS COMPRISING," the contents of which are incorporated herein by reference in their entirety . [0003] Sequence Listing Disclosure [0004] This application includes as part of its disclosure the Biological Sequence Listing, which was simultaneously submitted via EFS-Web. This biological sequence listing is contained in a file named "1156867o001613.txt", which was created on February 25, 2020, is 204,342 bytes in size, and is hereby incorporated by reference in its entirety. technical field [0005] The present disclosure relates to anti-ADAM12 agents, such as anti-ADAM12 antibodies (Abs), antigen-binding Ab fragments, multispecific Abs and antigen-binding Ab fragments, antibody-drug conjugates (ADCs), and chimeric antigen receptors (CARs). The ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/40C07K16/16C07K16/30
CPCC07K16/40C07K2317/24C07K2317/622C07K2317/73C07K14/7051C07K2319/33C07K2319/03A61P35/00A61K2039/812A61K2239/49A61K2239/31A61K39/4611A61K39/464458A61K2239/38A61K39/4631
Inventor A·B·库珀
Owner JAVELIN ONCOLOGY INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com